

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

EQA round: E23/19 - Hormones 2

Dead line: 06.08.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability								
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(193) Ferritin					26							23	21	91%	
Samples and groups	[µg/L]														
Sample A		306	43	14	26							23	23	100%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		342	10	3,0	7	0	CVPG	347	6,5	24%	263	431	7		
Other					19	0							16		
								3x 4/12, 1x 4/29, 4x 4/60, 1x 4/149, 3x 4/179, 2x 6/1, 1x 6/12, 2x 6/58, 1x 6/60, 1x 6/179					23	21	91%
Sample B		85,0	12	14	26							23	21	91%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		87,7	9,4	11	7	0	CVPG	91,1	2,4	24%	69,2	113	7		
Other					19	0							16		
								3x 4/12, 1x 4/29, 4x 4/60, 1x 4/149, 3x 4/179, 2x 6/1, 1x 6/12, 2x 6/58, 1x 6/60, 1x 6/179							
(320) LH					22							22	21	95%	
Samples and groups	[U/L]														
Sample A		47,9	7,5	16	22							22	22	100%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		47,2	3,5	7,5	7	0	CVPG	45,3	0,83	15%	38,5	52,1	7		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		39,4	2,7	6,8	6	0	CVPG	40,4	0,92	15%	34,3	46,5	6		
Other					9	0							9		
								1x 4/29, 4x 4/60, 4x 4/179							
Sample B		78,4	11	14	22							22	21	95%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		74,9	6,4	8,5	7	0	CVPG	74	1,5	15%	62,9	85,1	7		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		66,3	0,74	1,1	6	0	CVPG	66,1	1,4	15%	56,1	76,1	6		
Other					9	0							9		
								1x 4/29, 4x 4/60, 4x 4/179							
(321) FSH					22							22	21	95%	
Samples and groups	[U/L]														
Sample A		7,74	0,59	7,6	22							22	21	95%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		7,54	0,26	3,4	7	0	CVPG	7,23	0,10	15%	6,14	8,32	7		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		7,45	0,22	3,0	6	0	CVPG	7,26	0,16	15%	6,17	8,35	6		
Other					9	0							9		
								1x 4/29, 4x 4/60, 4x 4/179							
Sample B		5,31	0,55	10	22							22	22	100%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		4,93	0,25	5,1	7	0	CVPG	4,8	0,064	15%	4,08	5,52	7		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		5,47	0,38	6,9	6	0	CVPG	5,36	0,13	15%	4,55	6,17	6		
Other					9	0							9		
								1x 4/29, 4x 4/60, 4x 4/179							
(322) Prolactin					24							24	24	100%	
Samples and groups	[mU/L]														
Sample A		726	65	8,9	24							24	24	100%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		787	47	6,0	9	0	CVPG	767	13	16%	644	890	9		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		676	30	4,5	6	0	CVPG	646	14	16%	542	750	6		
Other					9	0							9		
								1x 4/29, 4x 4/60, 4x 4/179							
Sample B		575	44	7,7	24							24	24	100%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		613	24	4,0	9	0	CVPG	612	9,1	16%	514	710	9		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		542	16	3,0	6	0	CVPG	519	9,9	16%	435	603	6		
Other					9	0							9		
								1x 4/29, 4x 4/60, 4x 4/179							
(325) Insulin					7							7	7	100%	
Samples and groups	[mU/L]														
Sample A		119	27	23	7							7	7	100%	
Other					7	0							7		
								2x 4/1, 2x 4/12, 2x 4/60, 1x 4/179							
Sample B		42,0	11	25	7							7	7	100%	
Other					7	0							7		
								2x 4/1, 2x 4/12, 2x 4/60, 1x 4/179							
(326) Folate					24							24	23	96%	
Samples and groups	[nmol/L]														
Sample A		35,3	6,5	18	24							24	23	96%	
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		41,7	3,3	8,0	8	0	CVPG	41,9	0,78	27%	30,5	53,3	8		

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

EQA round: E23/19 - Hormones 2

Dead line: 06.08.2019

Test	[unit]						Comparability						N _{eva}	N _{suc}	S _{rel}
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL				
(326) Folate															
Samples and groups	[nmol/L]				24								24	23	96%
Sample A		35,3	6,5	18	24								24	23	96%
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		32,1	1,8	5,5	7	0	CVPG	31,8	0,48	27%	23,2	40,4	7		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		30,0	3,6	12	5	0	CVPG	29,4	0,36	27%	21,4	37,4	5		
Other					4	0							4		
															1x 4/149, 3x 4/179
Sample B		15,4	3,2	21	24								24	24	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		18,3	1,4	7,9	8	0	CVPG	18	0,53	27%	13,1	22,9	8		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		14,4	0,74	5,1	7	0	CVPG	14,2	0,26	27%	10,3	18,1	7		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		12,2	0,93	7,6	5	0	CVPG	11,5	0,16	27%	8,39	14,7	5		
Other					4	0							4		
															1x 4/149, 3x 4/179
(327) Vitamin B12															
Samples and groups	[pmol/L]				20								20	20	100%
Sample A		664	85	13	20								20	20	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		731	52	7,2	6	0	CVPG	712	15	20%	569	855	6		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		586	57	9,7	7	0	CVPG	578	10	20%	462	694	7		
Other					7	0							7		
															4x 4/60, 1x 4/149, 2x 4/179
Sample B		497	58	12	20								20	20	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		521	32	6,1	6	0	CVPG	529	8,7	20%	423	635	6		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		449	39	8,8	7	0	CVPG	433	9,3	20%	346	520	7		
Other					7	0							7		
															4x 4/60, 1x 4/149, 2x 4/179
(328) hGH															
Samples and groups	[mU/L]				5								5	5	100%
Sample A		39,1	0,96	2,5	5								5	5	100%
Other					5	0							5		
															2x 4/12, 3x 4/29
Sample B		15,2	0,89	5,9	5								5	5	100%
Other					5	0							5		
															2x 4/12, 3x 4/29
(329) IGF-1															
Samples and groups	[µg/L]				7								7	7	100%
Sample A		313	47	15	7								7	7	100%
Other					7	0							7		
															4x 4/29, 2x 4/164, 1x 4/183
Sample B		543	100	19	7								7	7	100%
Other					7	0							7		
															4x 4/29, 2x 4/164, 1x 4/183
(390) Renin															
Samples and groups	[ng/L]				6								6	4	67%
Sample A		35,7	7,5	21	6								6	4	67%
Other					6	0							6		
															1x 1/185, 3x 4/164, 2x 4/183
Sample B		36,5	4,5	12	6								6	5	83%
Other					6	0							6		
															1x 1/185, 3x 4/164, 2x 4/183
(392) IGF-BP3															
Samples and groups	[µg/L]				4								4	4	100%
Sample A		3880	410	11	4								4	4	100%
Other					4	0							4		
															4x 4/29
Sample B		4030	480	12	4								4	4	100%
Other					4	0							4		
															4x 4/29
(393) C-peptide															
Samples and groups	[pmol/L]				19								16	16	100%
Sample A		273	72	26	19								16	16	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		254	14	5,6	6	0	CVPG	250	15	20%	200	300	6		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		332	8,9	2,7	6	0	CVPG	325	12	20%	260	390	6		
Other					7	0							4		
															1x 4/29, 2x 4/164, 4x 4/179
Sample B		276	70	25	19								16	16	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		259	16	6,0	6	0	CVPG	252	20	20%	201	303	6		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		332	12	3,6	6	0	CVPG	327	6,4	20%	261	393	6		

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

EQA round: E23/19 - Hormones 2

Dead line: 06.08.2019

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(393) C-peptide					19								16	16	100%
Samples and groups	[pmol/L]														
Sample A		27,6	7,0	25	19								16	16	100%
Other					7	0							4		
							1x 4/29, 2x 4/164, 4x 4/179								
(394) SHBG					14								13	12	92%
Samples and groups	[nmol/L]														
Sample A		28,9	3,1	11	14								13	12	92%
Other					14	0							13		
							1x 3/25, 4x 4/1, 4x 4/12, 2x 4/29, 2x 4/60, 1x 4/179								
Sample B		28,7	2,6	9,1	14								13	13	100%
Other					14	0							13		
							1x 3/25, 4x 4/1, 4x 4/12, 2x 4/29, 2x 4/60, 1x 4/179								
(405) Parathyroid hormone (PTH)					15								15	15	100%
Samples and groups	[pmol/L]														
Sample A		10,4	2,6	25	15								15	15	100%
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		9,24	0,65	7,1	6	0	CVPG	9,53	0,39	23%	7,33	11,8	6		
Other					9	0							9		
							4x 4/1, 3x 4/60, 2x 4/179								
Sample B		20,2	4,2	21	15								15	15	100%
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		18,4	1,2	6,6	6	0	CVPG	19,1	0,82	23%	14,7	23,5	6		
Other					9	0							9		
							4x 4/1, 3x 4/60, 2x 4/179								
(407) Parathyroid hormone (PTH 1-84)					6								2	2	100%
Samples and groups	[pmol/L]														
Sample A		6,72	2,1	31	6								2	2	100%
Other					6	0							2		
							4x 4/60, 2x 4/164								
Sample B		13,0	3,0	23	6								2	2	100%
Other					6	0							2		
							4x 4/60, 2x 4/164								

st_kn_p

End of report

Printed: 14.08.2019